

HOUSE BILL 445

J1

9lr0991

By: **Delegates Hixson, Doory, Howard, Ivey, and Kaiser**

Introduced and read first time: February 4, 2009

Assigned to: Health and Government Operations

A BILL ENTITLED

1 AN ACT concerning

2 **Maryland Health Care Commission – Personalized Medicine – Study**

3 FOR the purpose of requiring the Maryland Health Care Commission to create a
4 certain stakeholder workgroup to study issues related to the implementation of
5 personalized medicine in the State; requiring the Commission to review certain
6 federal reports and recommendations, conduct a certain analysis, identify
7 certain obstacles to the implementation of personalized medicine, and make
8 certain recommendations; requiring the Commission to make a certain report to
9 certain committees of the General Assembly on or before a certain date; and
10 generally relating to the Maryland Health Care Commission and personalized
11 medicine.

12 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
13 MARYLAND, That:

14 (a) The Maryland Health Care Commission shall create a stakeholder
15 workgroup to study issues related to the implementation of personalized medicine in
16 the State.

17 (b) The stakeholder workgroup shall include:

18 (1) representatives from the schools of medicine in the State;

19 (2) representatives from the health insurance industry;

20 (3) representatives from the pharmaceutical industry; and

21 (4) any other interested stakeholder.

22 (c) In conducting the study, the Commission shall:

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 (1) review federal reports and recommendations related to
2 personalized medicine including the President's Council of Advisors on Science and
3 Technology report on Priorities for Personalized Medicine;

4 (2) analyze the impact of the federal Genetic Information
5 Nondiscrimination Act on the State's regulation of personalized medicine;

6 (3) identify obstacles to the implementation of personalized medicine,
7 including:

8 (i) laws and regulations regarding the protection of genetic
9 information;

10 (ii) healthcare worker attitudes, awareness, and education
11 related to personalized medicine;

12 (iii) the use of health information technology;

13 (iv) regulations on the pharmaceutical industry and on
14 laboratories; and

15 (v) reimbursement policies that may reduce access to
16 personalized medicine; and

17 (4) make recommendations, including legislative recommendations, to
18 reduce the obstacles to the implementation of personalized medicine in the State and
19 to otherwise advance the implementation of personalized medicine in the State.

20 (d) On or before December 30, 2009, the Commission shall report its findings
21 and recommendations, in accordance with § 2-1246 of the State Government Article,
22 to the Senate Finance Committee and the House Health and Government Operations
23 Committee.

24 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
25 June 1, 2009.